Zhang et al. showed that the objective response rate of antitumor therapy is inversely proportional to CRBN expression in several cancers, and multiple myeloma cells with loss of CRBN expression acquire resistance to lenalidomide and pomalidomide treatment [46, 47]. This evidence concerns the gene CRBN and plasma cell myeloma.